Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
Abroad (travel likely)RecruitingPHASE2
Conditions
Hairy Cell Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (For more information at the NIH Clinical Center contact National Cancer Institute Referral Office) · 888-624-1937
Study leads
Robert J Kreitman, M.D.
Principal Investigator
National Cancer Institute (NCI)